Nycomed enters major agreement with NPS Pharmaceuticals  

The Danish based pharmaceutical company has signed a DKK 550 million agreement which gives the rights to develop and market NPS's drug PREOS

Pharmaceutical company Nycomed has signed a DKK 550 million (USD 87 million) distribution and licence agreement with the US company NPS Pharmaceuticals which gives Nycomed the rights to develop and market the drug PREOS, currently under development for the treatment of osteoporosis. The agreement includes marketing in Europe, the Commonwealth of Independent States and Turkey.


The agreement between the two parties strengthens Nycomed's position on the rapidly growing market for drugs for the treatment of osteoporosis while NPS Pharmaceuticals can focus on preparing a launch of PREOS on the US market.


PREOS is a recombinant human parathyroid hormone. Clinical trials have shown that it rebuilds bones and reduces the risk of fractures of the spine in post-menopausal women with low bone mineral density. Osteoporosis and osteopenia (the precursor of osteoporosis) are reportedly affecting more than 55 million people in Europe. Post-menopausal women in particular are likely to suffer from it. The news is reported in a press release from Nycomed.


Link > Nycomed

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×